Amebiasis Market Report 2026

The amebiasis market size has grown strongly in recent years. It will grow from $0.88 billion in 2025 to $0.93 billion in 2026 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to prevalence of poor sanitation conditions, limited access to clean drinking water, reliance on metronidazole-based treatments, expansion of public health programs, availability of generic antiparasitic drugs.

The amebiasis market size is expected to see strong growth in the next few years. It will grow to $1.2 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to increasing investments in infectious disease control, rising demand for improved diagnostic tools, expansion of healthcare access in developing regions, growing focus on antimicrobial resistance management, advancement in targeted antiparasitic therapies. Major trends in the forecast period include increasing availability of combination drug therapies, rising focus on early diagnosis and treatment, expansion of oral antiparasitic medications, growing awareness of waterborne diseases, enhanced access to essential medicines.

The rising incidence of parasitic infections is expected to drive the growth of the amebiasis market going forward. Parasitic infections are diseases caused by protozoa, helminths, or ectoparasites that invade and multiply within human hosts, resulting in a broad range of gastrointestinal, systemic, or tissue-specific conditions. A key factor contributing to the increase in parasitic infections is inadequate sanitation, as limited access to clean water and effective waste management allows parasites to survive in the environment and spread more easily, increasing exposure risks within affected populations. Amebiasis treatment plays a critical role in addressing the growing burden of parasitic infections by supporting timely diagnosis and effective therapy, which helps interrupt transmission cycles and prevent progression to severe disease. For example, in February 2025, according to the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, approximately 100 million cases of amebiasis occur worldwide each year, primarily in developing regions, with nearly 90% remaining asymptomatic and contributing to continued community transmission. Therefore, the rising incidence of parasitic infections is driving the growth of the amebiasis market.

The increasing prevalence of poor sanitation is expected to propel the growth of the amebiasis market going forward. Poor sanitation refers to insufficient access to safely managed sanitation facilities, clean water, and basic hygiene services, which substantially raises the risk of parasitic infections such as those caused by Entamoeba histolytica. The widening sanitation gap is driven by factors including inadequate infrastructure, rapid urbanization, and restricted access to clean water, all of which support the persistence and spread of infection. Amebiasis can lead to a range of intestinal and extra-intestinal complications, such as diarrhea, abdominal pain, and liver abscesses, resulting in significant illness and death. For instance, in March 2023, according to the United Nations Children’s Fund (UNICEF), a US-based United Nations agency, around 3.6 billion people lacked access to safe household sanitation, while 1.8 billion people were without safe drinking water, contributing to an estimated 829,000 deaths each year associated with unsafe water, inadequate sanitation, and poor hygiene. Therefore, the growing prevalence of poor sanitation is driving the expansion of the amebiasis market.

Major companies operating in the amebiasis market are concentrating on the development of advanced treatment options, such as ready-to-use oral liquid metronidazole, to enhance patient adherence and therapeutic effectiveness. Ready-to-use oral liquid metronidazole is a pre-formulated liquid antibiotic used in the treatment of amebiasis, offering improved ease of administration for patients who have difficulty swallowing tablets. For example, in November 2023, Kesin Pharma Corporation, a US-based pharmaceutical company, received approval from the U.S. Food and Drug Administration for Likmez (metronidazole) oral suspension, 500 mg/5 mL, making it the first ready-to-use oral liquid formulation of metronidazole. This oral suspension provides a child-friendly treatment option that supports accurate dosing and improved compliance with prescribed regimens. Additionally, the liquid formulation allows for flexible dosing, enabling healthcare providers to tailor treatment based on individual patient requirements and infection severity.

Major companies operating in the amebiasis market are Pfizer Inc., Merck & Co. Inc., Sanofi SA, AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Cipla Limited, Lupin Limited, Zydus Lifesciences Limited, Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Limited, Alkem Laboratories Limited, Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Limited, Mylan NV, Glenmark Pharmaceuticals Limited, Torrent Pharmaceuticals Limited.

North America was the largest region in the amebiasis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the amebiasis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the amebiasis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the amebiasis market by increasing costs of imported active pharmaceutical ingredients, formulation chemicals, packaging materials, and diagnostic supplies used in treatment and disease management. Developing regions in Asia-Pacific, Africa, and Latin America are most affected due to reliance on imported pharmaceuticals, while developed markets face pricing pressure on finished drug products. These tariffs are impacting affordability and procurement timelines. However, they are also encouraging local pharmaceutical manufacturing, regional API production, and improved supply chain resilience for essential antiparasitic medications.

The amebiasis market research report is one of a series of new reports that provides amebiasis market statistics, including amebiasis industry global market size, regional shares, competitors with a amebiasis market share, detailed amebiasis market segments, market trends and opportunities, and any further data you may need to thrive in the amebiasis industry. This amebiasis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Amebiasis is an intestinal infection caused by the parasite Entamoeba histolytica and is commonly associated with symptoms such as diarrhea, abdominal pain, and, in some cases, liver abscesses. The condition is treated using medications such as metronidazole and tinidazole, which act by targeting the parasite within the gastrointestinal tract and affected tissues.

The primary drug types used in the treatment of amebiasis include metronidazole, paromomycin, and tinidazole. Metronidazole is an antibiotic that eliminates certain bacteria and parasites by interfering with their DNA, making it effective in treating infections such as amebiasis. The different routes of administration include oral and intravenous delivery, and these treatments are utilized across various settings, including hospitals and pharmacies.

The amebiasis market includes revenues earned by entities by providing services such as medical consultation and treatment management, vaccination and preventive services, pharmaceutical services, and diagnostic testing services. The market value includes the value of related goods sold by the service provider or included within the service offering. The amebiasis market also includes sales of antiprotozoal medications, diagnostic kits, vaccines, and probiotics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.